Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Total Liabilities (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Total Liabilities for 16 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities rose 7.98% year-over-year to $7.5 million, compared with a TTM value of $7.5 million through Sep 2025, up 7.98%, and an annual FY2024 reading of $7.1 million, down 20.8% over the prior year.
  • Total Liabilities was $7.5 million for Q3 2025 at China Pharma Holdings, up from $7.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $16.6 million in Q4 2021 and bottomed at $6.9 million in Q2 2024.
  • Average Total Liabilities over 5 years is $10.7 million, with a median of $11.3 million recorded in 2021.
  • The sharpest move saw Total Liabilities grew 26.83% in 2021, then plummeted 39.63% in 2024.
  • Year by year, Total Liabilities stood at $16.6 million in 2021, then dropped by 18.87% to $13.5 million in 2022, then plummeted by 33.2% to $9.0 million in 2023, then fell by 20.8% to $7.1 million in 2024, then grew by 4.92% to $7.5 million in 2025.
  • Business Quant data shows Total Liabilities for CPHI at $7.5 million in Q3 2025, $7.3 million in Q2 2025, and $7.2 million in Q1 2025.